Pure Global
NCT06158503

Glycemic Control and Osteohealth in Adults Living With Type 1 Diabetes

GLYcemic COntrol and OSTEOhealth: Impact of Short-Term Glycemic Control on Skeletal Outcomes in Adults With Type 1 Diabetes
Centre hospitalier de l'Université de Montréal (CHUM)·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Type 1 Diabetes
Drug/Device/Intervention
AID
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Location
Montreal, Canada
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2024
End date
Jun 30, 2027
Enrollment
25 participants
Primary outcome

Bone remodeling improvement

Summary

Bone damage is frequently observed in type 1 diabetes, and hyeprglycemia is associated with
 an increased risk of fracture. This pilot study in 25 people living with type 1 diabetes aims
 to determine whether the introduction of an automated insulin delivery (AID) system improves
 bone markers through rapide optimization of glycemic control. Measurements will be taken
 before the start of AID, 2 months and 4 months afterwards.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06158503
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06158503 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre hospitalier de l'Université de Montréal (CHUM) and is currently Not yet recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.